FDA Approves Treatment for Smallpox Vaccination Side Effects
DynPort Vaccine Company LLC (Frederick, MD, www.dynport.com) has received approval from the US Food and Drug Administration for a drug to treat adverse reactions to vaccinia virus, the live vaccine used in smallpox vaccines.
Because the smallpox vaccination contains a live virus, inoculated patients may develop serious, potentially life-threatening side effects including a severe, toxic rash that can spread to other individuals. In the past, serious reactions had occurred in 1000 out of every 1 million people vaccinated, according the Centers for Disease Control and Prevention.
DynPort’s intravenous vaccinia immune globulin (VIGIV) treatment contains purified antibodies specific to the vaccinia virus and is designed to help patients recover from severe rashes caused by the smallpox vaccine. Currently, the treatment is available only to the US military.
The company developed the VIGIV treatment platform as part of the Department of Defense’s Joint Vaccine Acquisition Program (JVAP) and is the first FDA-licensed product for DynPort and JVAP. VIGIV received fast-track and orphan drug status from FDA. Other products under development using the VIGIV technology include vaccines for botulinum, plague, tularemia, and Venezuelan equine encephalitis.
–Kaylynn Chiarello
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.